|
Synonyms: MPDL3280A | Tecentriq®
atezolizumab is an approved drug (FDA (2016), EMA (2017))
Compound class:
Antibody
Comment: Atezolizumab (MPDL3280A) is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence analysis using the light chain variable region of atezolizumab provides a 100% match to sequence 21 from patent US8217149. An X-ray crystal structure of the PD-L1/atezolizumab complex has been submitted to the RCSB PDB (accession 5X8L) [3]. |
| Bioactivity Comments |
| The development and use of atezolizumab is claimed in patent US8217149 [2]. The actual antibody clone selected as the lead is not disclosed in the patent, so affinity data in the table below is representative of preferred antibodies noted in the patent document, for example YW243.55.S70. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
